Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
R. Tasneen, D. S. Mortensen, P. J. Converse, M. E. Urbanowski, A. Upton, N. Fotouhi, E. Nuermberger, N. Hawryluk
This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.
bioRxiv · Feb 10, 2021Pathology